April 4 (Reuters) - Amylyx Pharmaceuticals ( AMLX ) said
on Thursday it would withdraw its amyotrophic lateral sclerosis
(ALS) drug from the U.S. and Canada markets after the treatment
failed in a crucial late-stage trial.